Dendritic cell immunotherapy for stage IV melanoma

Melanoma Research

Volumn 17, Issue 5, 2007, Pages 316-322

  O'Rourke, Michael G E ^c   Johnson, Maree K ^c   Lanagan, Catherine M ^e   See, Janet L ^c   O'Connor, Linda E ^e   Slater, Gregory J ^b   Thomas, David ^a   Lopez, José Alejandro ^d,e   Martinez, Nathan R ^e   Ellem, Kay A O ^e   Schmidt, Christopher W ^d,e  

^a Queensland Radium Institute   (Australia)

^b Queensland X Ray   (Australia)

^c Mater Adults Hospital   (Australia)

^d Australian Centre for Vaccine Development   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Complete response; Dendritic cell; Immunotherapy; Melanoma

Indexed keywords

DENDRITIC CELL VACCINE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DENDRITIC CELL; FEMALE; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL;

ADULT; AGED; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34648860544     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282c3a73b     Document Type: Article

References (25)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012.
2. O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003; 52:387-395.
3. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest 2003; 21:873-886.
4. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomised phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17:563-570.
5. Wang TS, Lowe L, Smith JW, Francis IR, Sondak VK, Dworzanian L, et al. Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg 1998; 24:915-919.
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
7. Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci U S A 1978; 75:5132-5136.
8. Feuerstein B, Berger TG, Maczek C, Roder C, Schreiner D, Hirsch U, et al. qA method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000; 245:15-29.
9. John J, Hutchinson J, Dalgleish A, Pandha H. Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction. J Immunol Methods 2003; 272:35-48.
10. Westermann J, Korner IJ, Kopp J, Kurz S, Zenke M, Dorken B, et al. Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties. Cancer Immunol Immunother 2003; 52:194-198.
11. John J, Dalgleish A, Melcher A, Pandha H. Cryopreserved dendritic cells for intratumoral immunotherapy do not require re-culture prior to human vaccination. J Immunol Methods 2005; 299:37-46.
12. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A 1996; 93:2588-2592.
13. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193:233-238.
14. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 2000; 105:R9-R14.
15. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004; 10:887-892.
16. Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-480.
17. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-915.
18. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216:463-482.
19. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61:6451-6458.
20. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-332.
21. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
22. Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 2006; 55:1209-1218.
23. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006; 12:2353s-2358s.
24. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274-278.
25. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA Class I Antigen Expression on Outcome. J Clin Oncol 2002; 20:2067-2075.